Literature DB >> 34150089

Ultrasonography-guided radiofrequency ablation combined with lauromacrogol sclerotherapy for mixed thyroid nodules.

Rui Shen1, Rongqi Cheng1, Henghua Zhou2, Xiaoping Wang3, Chao Chen4, Yifei Gong3, Xumin Cen1, Jie Yuan1, Fei Xu1, Yanping Wu1.   

Abstract

OBJECTIVE: To evaluate the safety and effectiveness of ultrasonography-guided radiofrequency ablation combined with lauromacrogol foam sclerotherapy for the treatment of mixed thyroid nodules.
METHODS: One hundred and nineteen patients with benign mixed thyroid nodules were included in this study. In all patients, radiofrequency ablation was performed on the solid components of nodules, and the cystic areas of nodules were treated with aspiration, irrigation with lauromacrogol injection and foam sclerotherapy. The nodule volume reduction ratio and thyroid-related laboratory tests were measured during operation and at 1, 3, 6, and 12 months after operation, and intraoperative and postoperative complications were recorded.
RESULTS: A total of 136 mixed thyroid nodules from 119 patients all achieved complete ablation. At 1, 3, 6, and 12 months after treatment, the nodule volume decreased gradually while the volume reduction ratio increased gradually (P<0.05). The thyroid function of all patients returned to normal after operation, but 3 patients exhibited cyst recurrence. After the operation, no serious complications occurred.
CONCLUSION: Ultrasonography-guided radiofrequency ablation combined with lauromacrogol sclerotherapy is a safe and effective method for the treatment of mixed thyroid nodules with less surgical trauma and low incidence of complications. AJTR
Copyright © 2021.

Entities:  

Keywords:  Thyroid nodule; lauromacrogol; radiofrequency ablation; sclerotherapy

Year:  2021        PMID: 34150089      PMCID: PMC8205792     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  6 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  Current oncologic applications of radiofrequency ablation therapies.

Authors:  Dhruvil R Shah; Sari Green; Angelina Elliot; John P McGahan; Vijay P Khatri
Journal:  World J Gastrointest Oncol       Date:  2013-04-15

3.  Associations of noniodized salt and thyroid nodule among the Chinese population: a large cross-sectional study.

Authors:  Zexin Chen; Weimin Xu; Yangmei Huang; Xingyi Jin; Jin Deng; Sujuan Zhu; Hui Liu; Shanchun Zhang; Yunxian Yu
Journal:  Am J Clin Nutr       Date:  2013-07-10       Impact factor: 7.045

4.  Partially cystic thyroid nodules: ultrasound findings of malignancy.

Authors:  Jang Mi Park; Yoonjung Choi; Hyon Joo Kwag
Journal:  Korean J Radiol       Date:  2012-08-28       Impact factor: 3.500

5.  Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases.

Authors:  Tiphaine C Martin; Kristina M Ilieva; Alessia Visconti; Michelle Beaumont; Steven J Kiddle; Richard J B Dobson; Massimo Mangino; Ee Mun Lim; Marija Pezer; Claire J Steves; Jordana T Bell; Scott G Wilson; Gordan Lauc; Mario Roederer; John P Walsh; Tim D Spector; Sophia N Karagiannis
Journal:  Cells       Date:  2020-03-09       Impact factor: 6.600

Review 6.  Effect of antithyroid antibodies on women with recurrent miscarriage: A meta-analysis.

Authors:  Jilai Xie; Lihong Jiang; Annapurna Sadhukhan; Songqing Yang; Qiuping Yao; Ping Zhou; Jinpeng Rao; Min Jin
Journal:  Am J Reprod Immunol       Date:  2020-04-11       Impact factor: 3.886

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.